Entropy Granted Australian Patent for Method of Administering Psychedelic Drug for Pain Disorders; Shares Jump Nearly 7%
MT Newswires Live
Yesterday
Entropy Neurodynamics (ASX:ENP) was granted an Australian patent covering its two-phase dosing method of administering psychedelic drug psilocybin, psilocin, and related forms to treat a range of psychological and nociplastic pain disorders, according to a Thursday Australian bourse filing.
The proprietary dosing method covered by the patent, which will run through to 2042, includes a loading dose followed by a controlled maintenance infusion, the filing said.
The patent protects elements, such as the rapid induction of the psychedelic state or therapeutic window, within a defined period of five to 30 minutes and controlled maintenance of drug levels over the treatment period.
The company's shares rose nearly 7% in recent trading on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.